Transcriptomic and genetic studies identify NFAT5 as a candidate gene for cocaine dependence

N Fernández-Castillo1,2,3, J Cabana-Domínguez1,2, J Soriano4, C Sánchez-Mora5,6,7, C Roncero5,7,8,9, L Grau-López2,7,8,9, E Ros-Cucurull5,8,9, C Daigre5,7,8,9, MMJ van Donkelaar10,11, B Franke10,11,12, M Casas5,7,8,9, M Ribasés5,6,7,13 and B Cormand1,2,3,13

Cocaine reward and reinforcing effects are mediated mainly by dopaminergic neurotransmission. In this study, we aimed at evaluating gene expression changes induced by acute cocaine exposure on SH-SY5Y-differentiated cells, which have been widely used as a dopaminergic neuronal model. Expression changes and a concomitant increase in neuronal activity were observed after a 5 μM cocaine exposure, whereas no changes in gene expression or in neuronal activity took place at 1 μM cocaine. Changes in gene expression were identified in a total of 756 genes, mainly related to regulation of transcription and gene expression, cell cycle, adhesion and cell projection, as well as mitogen-activated protein kinase (MAPK), CREB, neurotrophin and neuregulin signaling pathways. Some genes displaying altered expression were subsequently targeted with predicted functional single-nucleotide polymorphisms (SNPs) in a case–control association study in a sample of 806 cocaine-dependent patients and 817 controls. This study highlighted associations between cocaine dependence and five SNPs predicted to alter microRNA binding at the 3′-untranslated region of the NFAT5 gene. The association of SNP rs1437134 with cocaine dependence survived the Bonferroni correction for multiple testing. A functional effect was confirmed for this variant by a luciferase reporter assay, with lower expression observed for the rs1437134G allele, which was more pronounced in the presence of hsa-miR-509. However, brain volumes in regions of relevance to addiction, as assessed with magnetic resonance imaging, did not correlate with NFAT5 variation. These results suggest that the NFAT5 gene, which is upregulated a few hours after cocaine exposure, may be involved in the genetic predisposition to cocaine dependence.

INTRODUCTION
Cocaine is a psychostimulant drug of abuse and its use has become a public health problem worldwide. Cocaine’s pleasurable and addictive effects are thought to be mediated mainly through dopamine (DA), which is a key neurotransmitter in reward pathways.1 Cocaine binds the DA transporter producing an increase in DA concentration at the synapses and thus stimulating neurons in brain regions involved in reward and reinforcement behavior.1–3

Cocaine’s chronic and acute effects on gene expression have been studied using a broad range of animal models and experimental paradigms and procedures, including human post-mortem samples.4,5 These studies have identified gene expression changes in the brain related to diverse functional categories including synaptic communication and neuroplasticity, receptors, ion channels and transporters, cytoskeleton, extracellular matrix, oligodendrocytes and myelin, mitochondrial function, apoptosis and cell death, transcription factors and signal transduction. Moreover, two important pathways have been found affected by changes in gene expression: the mitogen-activated protein kinase (MAPK) and the synaptic long-term potentiation signal transduction pathways.4,5

The repeated use of cocaine induces molecular and cellular adaptations in the central nervous system, such as synaptic changes and neuronal remodeling, and as the consumption becomes chronic those adaptations become stable.6 Individual’s genetic background and environment determine the initial sensitivity to first drug exposure and how individual nerve cells and circuits adapt to chronic drug exposure, which could establish the development of addiction in some individuals but not others.7 Around 15–16% of cocaine users develop dependence, and heritability for cocaine addiction has been estimated around 60–70%.8,9 Some of those genetic factors may lie in genes that mediate acute and chronic cocaine’s effects, conferring initial vulnerability to the establishment of drug-induced adaptations.

Compared with other drugs of abuse, relatively few association studies have been performed on cocaine dependence, and little is known about the genetic susceptibility to this psychiatric disorder.11 Some association studies have focused on candidate genes, especially on DA-related genes, the majority failing to detect associations or showing controversial results. Only

1Departament de Genètica, Facultat de Biologia, Universitat de Barcelona, Barcelona, Catalonia, Spain; 2Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain; 3Institut de Biomedicina de la Universitat de Barcelona, Barcelona, Catalonia, Spain; 4Department d’Estructura i Constituents de la Matèria, Universitat de Barcelona, Barcelona, Catalonia, Spain; 5Department of Psychiatry, Hospital Universitari Vall d’Hebron, Barcelona, Spain; 6Psychiatric Genetics Unit, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; 7Biomedical Network Research Center on Mental Health (CIBERSAM), Barcelona, Spain; 8Addiction and Dual Diagnosis Unit, Psychiatric Service, Hospital Universitari Vall d’Hebron, Agència de Salut Pública, Barcelona, Spain; 9Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; 10Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands; 11Donors Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, The Netherlands; 12Department of Psychiatry, Radboud University Medical Center, Nijmegen, The Netherlands.

Correspondence: Dr N Fernández-Castillo or Dr B Cormand, Departament de Genètica, Facultat de Biologia, Universitat de Barcelona, Avinguda Diagonal 645, edifici annex, 3ª planta, Barcelona 08028, Spain.

Email: noelfernandez@ub.edu or bccormand@ub.edu

These authors contributed equally to this work.

Received 15 August 2015; accepted 19 August 2015
associations with two genes, CNR1 (cannabinoid receptor 1, brain) and CHRNA5 (cholinergic receptor, nicotinic, alpha 5, neuronal) have been replicated so far.11–13 Other studies have assessed hundreds of single-nucleotide polymorphisms (SNPs) in multiple genes within candidate systems, and two genome-wide association studies have been reported in cocaine dependence, identifying shared as well as specific associations in European Americans and in African American populations.14–17

We aimed at discovering novel genes involved in the susceptibility to cocaine dependence that could mediate its effects. Under the hypothesis that sequence variants in genes showing differential expression induced by cocaine may contribute to cocaine dependence, and considering the essential role that DA has in cocaine’s effects and addiction, we designed a two-stage study by (i) identifying cocaine-induced changes in gene expression in a dopaminergic neuron-like model (SH-SYSY) using microarray technology and (ii) subsequently considering differentially expressed genes as potential candidates for cocaine dependence, by assessing predicted functional SNPs in these genes through a case–control association study.

MATERIALS AND METHODS

A brief description of the materials and methods is presented below. For detailed information of all procedures see Supplementary Information.

Cell culture and cocaine treatments

SH-SYSY cells (ATCC, LGC Standards, Middlesex, UK) were differentiated with retinoic acid (Sigma-Aldrich Corporate, St. Louis, MO, USA) during 7 days at a final concentration of 10 μM supplemented on the media (50.50 Dulbecco’s modified Eagle’s medium:F12, 10% fetal bovine serum and 1% P/S, Gibco, Life Technologies, Carlsbad, CA, USA). SH-SYSY differentiation was assessed by changes compatible with neuron-like morphology and neurite outgrowth, expression of tyrosine hydroxylase as a dopaminergic neuronal marker by western blot, and cell cycle analysis (Supplementary Figure 1). Cytotoxicity of cocaine was assessed with XTT assays (Cell Proliferation Kit II, Roche Life Sciences, Branford, CT, USA) at 0, 1, 5, 10, 15 and 20 μM of cocaine–HCl. The range of cocaine concentrations were selected based on concentrations determined in human plasma and brain in different studies.11–13 For gene expression analysis, cocaine treatment was performed on differentiated SH-SYSY cells at 0, 1 and 5 μM, selected on the basis of a previous microarray study25 and the range observed in cocaine abusers.12,13 After 30 min of exposure, the medium was replaced and cells were retrieved at 6 or 24 h.

Microarray and qRT-PCR experiments

RNA was isolated from nine dishes per condition (RNaseasy Mini Kit, Qiagen, Hilden, Germany) and pools of three dishes were hybridized to the GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA, USA). Microarray data have been deposited in NCBI’s Gene Expression Omnibus (GEO) and are accessible through GEO Series accession number GSE71939 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71939). For quantitative real-time (qRT-PCR) validation, we initially selected genes showing differences in expression $\geq$ 1.5-fold, a total of 143. From those we considered genes included in representative enriched functional categories, pathways or gene networks. Finally, we selected eight genes based on their functions and possible involvement in mediating cocaine effects and neuroadaptations, in which expression had not previously been found to be altered by cocaine. Selected genes were validated using qRT-PCR and further assessed in new experiments at different time points (2, 4, 5, 6, 7, 8 and 10 h) after a cocaine acute exposure (0 vs 5 μM) with three replicates per condition. We performed a relative quantification of the results of the qRT-PCR experiments using glyceraldehyde-3-phosphate dehydrogenase and hypoxanthine phosphoribosyltransferase (HPRT1) expression for normalization.

Calcium imaging and neuronal activity monitoring

We used calcium imaging (Fluo-4-AM) to monitor changes in neuronal activity in differentiated SH-SYSY cells at 0, 1, 5 and 10 μM cocaine–HCl exposure as previously described.26 Recordings were performed during 15 min per condition, assessing over eight replicates (160–240 active neurons per condition).

Subjects

Seven genes showing differential expression profiles after an acute cocaine treatment were selected to perform a case–control association study on cocaine dependence. The clinical sample included 806 cocaine-dependent subjects according to DSM-IV TR criteria (Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text revision) seeking treatment in the ‘Addiction and Dual Diagnosis Unit’ of Vall d’Hebron Hospital (Barcelona, Spain) and 817 sex-matched healthy controls (see Supplementary Table 1 for details). The controls were recruited at the Blood and Tissues Bank of Vall d’Hebron Hospital; none of them had injected drugs intravenously. All individuals were Spanish and Caucasian, with the two last names (one from each parent) of Spanish origin. All of them signed the informed consent, previously approved by the Ethics Committee and were evaluated according to the ‘Addiction and Dual Diagnosis Unit’ protocol.27 DNA samples were isolated from peripheral blood. Population stratification was previously discarded in our sample.15

SNP selection and genotyping

A total of 22 SNPs within seven candidate genes were selected based on their predicted functional effect using the FuncPred software (http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm) and two additional SNPs at the SEMA6D gene associated with substance dependence in a previous genome-wide association study28 were also included in the assay. Finally, 23 SNPs were successfully genotyped with KASP technology with an average genotype call rate of 98.2%, and further evaluated in a case–control association study.

Functional evaluation of SNP effects on microRNA regulation using a luciferase assay

The effect of SNPs showing consistent predictions on microRNA regulation (using different software tools, see Supplementary Information) was experimentally tested by a luciferase reporter system in HEK and in SH-SYSY cells. The 3‘-untranslated regions containing both alleles of each SNP were cloned in the pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega, Madison, WI, USA) and cotransfected into HEK and SH-SYSY cells with the corresponding microRNA cloned in a pCMV-MIR vector (Origene, Rockville, MD, USA). Luciferase expression was assessed using the Dual-luciferase Reporter Assay System (Promega).

Neuroimaging genetics studies

The effect of NFA75 SNPs on regional brain volumes was tested using neuromaging and genetic data of 1300 self-reported healthy adults from the Dutch Cognomics Resource Brain Imaging Genetics (http://www.cognomics.nl).29 Seven regions of interest known to be involved in drug addiction30 (orbitofrontal cortex, prefrontal cortex, nucleus accumbens, putamen, caudate nucleus, hippocampus and insula) were assessed in the discovery sample (n = 645, scanned at 1.5 Tesla) and then in the replication sample (n = 655, scanned at 3 Tesla; Supplementary Table 2).

Statistical analyses

We used the afiy library to perform background correction, normalization and summarization, considering the background method, the Robust Multichip Average method and the median polish method, respectively.31 Genes were filtered by signal (threshold log2(40)), and the expression profiles were compared using the limma library. We used DAVID Annotation Tool32 for the functional enrichment clustering and the Ingenuity Pathway Analysis v8.8 software (http://www.ingenuity.com/products/pga) for gene network and canonical pathway enrichment analyses. WebGASTL was used for microRNA-binding site enrichment analyses considering upregulated and downregulated subsets of genes separately.33

The minimal statistical power in the case–control association study was estimated post hoc considering the SNP with the lowest minimum allele frequency (MAF = 0.143) and assuming an additive model of inheritance, with an estimated statistical power of 98% using the software Power Calculator for Genetic Studies (http://sph.umich.edu/csg/abecasis/CaTS). Analysis of Hardy–Weinberg equilibrium and the comparison of genotyping
frequencies between cases and controls under an additive model were performed using the SNPassoc R package. Significant P-values were adjusted for age. Bonferroni correction for multiple testing was applied considering 22 independent tests (P < 0.0022).

For cytotoxicity, qRT-PCR, calcium imaging and luciferase experiments, differences between conditions were evaluated with the IBM SPSS Statistics Software Version 22.0 (Released 2013; IBM, Armonk, NY, USA) using a Mann–Whitney non-parametric U-test, as normality was rejected using the Kolmogorov–Smirnov test (as expected, given the small number of samples), and statistical significance was set at P < 0.05. Brain volume analyses were performed by linear regression using PLINK software (http://pngu.mgh.harvard.edu/~purcell/plink/).

RESULTS

Under the hypothesis that cocaine-induced gene expression changes may highlight novel candidate genes predisposing to cocaine dependence, we performed an in vitro study in a dopaminergic neuron-like model to assess transcriptional changes induced by cocaine. Subsequently, we tested those genes showing differential expression as potential candidates for cocaine dependence through a case–control association study.

Cocaine-induced changes in gene expression in SH-SYSY cells differentiated to dopaminergic neurons

SH-SYSY cells differentiated to dopaminergic neurons (Supplementary Figure 1) showed no cocaine cytotoxic effects at any of the conditions under study (data not shown), and gene expression experiments were conducted at 6 or 24 h after 30 min of cocaine treatment at 0, 1 and 5 μM. After 6 h of an acute 30-min exposure to 5 μM cocaine, 756 genes exhibited significantly altered expression levels when compared to untreated cells (419 upregulated and 337 downregulated; Supplementary Table 3). Analysis of functional group over-representation identified several processes, including regulation of transcription, chromatin modification, focal adhesion and cell projection, and also neurotrophin and MAPK signaling pathways, among others (Figure 1a). Gene network construction showed a highly scored network (score = 34, Figure 1b) involved in molecular transport, cellular development and cell-to-cell signaling and interaction. The canonical pathways ‘neuregulin signalling’ and ‘cyclical AMP response element-binding protein (CREB) signaling in neurons’ were also altered (Supplementary Figure 2). The analysis of enrichment of microRNA-binding sites identified miR-124a, with predicted targets in 22 genes upregulated by cocaine (see Supplementary Table 4). The validation assays of expression patterns at different time points for eight genes showing expression differences > 1.5-fold and involved in neuroadaptation, axon guidance, neuroplasticity, neurite outgrowth, neurotrophin signaling pathway or transcription regulation, confirmed increased expression around 6 h after cocaine exposure for ectodermal–neural cortex 1 (ENC1), nuclear factor-activated T-cells 5 (NFAT5), E74-like factor 1 (ELF1), protein phosphatase 1 regulatory subunit 9A (PPP1R9A), insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) and neuregulin 1 (NRG1), and decreased expression for semaphorin 6D (SEMA6D) (Figure 2).

No differences in gene expression were observed in the microarray experiments when cells were treated with 1 μM cocaine or 24 h after exposure. In order to explain the lack of changes observed at this concentration, we hypothesized that neuronal activation may co-occur with transcriptional changes above a specific threshold of cocaine concentration, and 1 μM cocaine may not be sufficient to induce detectable changes in neuronal activity nor in gene expression. For this purpose, we investigated neuronal network activity by means of calcium imaging after exposure to different cocaine concentrations (Figure 3a). We observed a concentration-dependent progressive increase in neuronal response and firing amplitude (Figures 3b and c). No changes in the percentage of active neurons were observed when we compared 0 and 1 μM cocaine treatment (22 and 26%, P = 0.44), nor in the average number of firing/neuron (0.4 and 0.5 firings/neuron, P = 0.40) (Figures 3d and e). Increases in active neurons and a higher number of firings/neuron, however, were detected after exposure to 5 μM (64%, P = 8.7e–05; 1.4 firings/neuron, P = 0.047) or 10 μM cocaine–HCl (67%, P = 1.5e–06; 1.9 firings/neuron, P = 3.6e–03) compared to 0 μM (Figures 3d and e). The absence of differences in neuronal activity below 1 μM correlates with the lack of differences observed in gene expression at this cocaine concentration.

Case–control association study on cocaine dependence

The seven genes that showed cocaine-induced expression changes validated by qRT-PCR were subsequently considered as candidates to contribute to cocaine dependence susceptibility. Twenty-three potentially functional SNPs in genes showing cocaine-induced changes in expression levels (NFAT5, ELF1, PPP1R9A, SEMA6D and IGF2BP3) were subsequently followed-up in a case–control association study of 806 cocaine-dependent patients and 817 sex-matched healthy controls. All SNPs, except for rs854524, not considered in the subsequent analyses, were in Hardy–Weinberg equilibrium both in cases and in controls (Supplementary Table 5).

The single-marker analysis showed that five SNPs in the 3′ untranslated region of the NFAT5 gene were associated with cocaine dependence, and two of them (rs1437134 and rs7359336, in high linkage disequilibrium) survived the Bonferroni correction for multiple testing (Table 1; Supplementary Table 5; Supplementary Figure 3). All five variants were predicted to alter binding sites for microRNAs (Supplementary Figure 4) and two of them, rs1437134 and rs11641233, were predicted to alter hsa-miR-509 and hsa-miR-649 binding to the NFAT5 messenger RNA by at least three different software tools. We subsequently focused on these two SNPs and performed a luciferase reporter assay in HeLa and SH-SYSY cells. A significant decrease in gene expression was observed for allele rs1437134G compared to allele rs1437134A, both in HeLa and in SH-SYSY cells (9 and 13%, respectively; Figure 4). In the presence of the microRNA hsa-miR-509, the decrease in gene expression shown by rs1437134G, compared to rs1437134A, was more pronounced in both cell lines (31% in HeLa and 21% in SH-SYSY; Figure 4). In contrast, no effect on gene expression was detected for rs11641233 in the presence of hsa-miR-649 (data not shown).

Finally, as NFAT5 is a member of the NFAT protein family, involved in axon guidance, and it is highly expressed in the developing and adult brain, we tested possible effects of NFAT5 variation on brain volumes using brain imaging data. In this way, we aimed at identifying potential mechanisms mediating the effect of this gene on addiction risk. However, no significant correlations were observed between brain volumes in the regions of interest and any of the SNPs investigated (Supplementary Table 6).

DISCUSSION

This study aimed at uncovering genes mediating cocaine’s effects in an in vitro model that could eventually participate also in the susceptibility to cocaine dependence. For this purpose, we first identified genes showing differential expression under cocaine exposure in a dopaminergic cell model, and we subsequently investigated their possible role in the predisposition to cocaine dependence by assessing functional common genetic variants through a case–control study. The results of our experimental design point at NFAT5, which is upregulated by cocaine and bears functional risk variants for cocaine dependence.
To our knowledge, this is the first study assessing gene expression changes induced by cocaine in a dopaminergic cell model, with dopaminergic neurons being the key of the reward system and cocaine pleasurable effects. For this purpose, we used the SH-SY5Y cell line differentiated with retinoic acid, which shows neuron-like morphology, has increased DA content, expresses neuronal and dopaminergic markers, has functional DA transporter, and features excitability, potential propagation and enhanced dopaminergic neurotransmission.35–38

In vitro studies assessing the effect of cocaine exposure on gene expression have previously been performed in neuronal progenitor or fetal cells to study prenatal brain alterations, and showed changes in immune and inflammatory responses, and cell-death related genes.25,39,40 Under our experimental conditions, changes in expression were detected for genes involved in transcription, transport, cell cycle, cell projection and adhesion, and MAPK and CREB signaling, which is in agreement with previous gene expression studies after cocaine abuse performed in humans and animals.4,5 Several genes showing differential expression in our study were also found altered in previous studies performed in human post-mortem samples and rat models, including ADORA1 (adenosine A1 receptor), CALM2...
after 5 detected the effect of cocaine exposure on SH-SY5Y cells at 6 h in vitro to produce those cocaine effects, which may correlate with our changes after exposure to 5 μg kg⁻¹ during the 30 min after an intravenous cocaine dose of 0.1 - 0.6 mg kg⁻¹ showing gene expression changes 24 and 48 h after only 1 higher intravenous doses (0.3 and 0.6 mg kg⁻¹ changes under 1 activity after exposure to 5 μg kg⁻¹ by cocaine abusers). Thus, 1’ of the brain (after a 0.1-mg kg⁻¹ carbachol effects,47 that revealed significant increases in neuronal activity and expression studies detecting cocaine concentrations in the caudate-putamen, study by Crawford et al.25 in human neuronal progenitor cells showing gene expression changes 24 and 48 h after only 1 μM cocaine treatment. The results of the transcription analysis correlated with our calcium imaging experiments, a technique previously employed in SH-SY5Y cells to assess caffeine and carbococh effects,47 that revealed significant increases in neuronal activity after exposure to 5 μM cocaine, but almost no activity changes under 1 μM cocaine treatment. This is consistent with previous studies detecting cocaine concentrations in the caudate-putamen of cocaine abusers in the range of 0.8 – 1.8 μM (average about 1 μM) during the 30 min after an intravenous cocaine dose of 0.1 - mg kg⁻¹, a dose that was not sufficient to produce a subjective ‘high’, rush and craving in humans;1 these were only observed at higher intravenous doses (0.3 and 0.6 mg kg⁻¹, commonly used by cocaine abusers). Thus, 1 μM cocaine in dopaminergic regions of the brain (after a 0.1-mg kg⁻¹ dose) would not be enough to produce those cocaine effects, which may correlate with our findings obtained in neuronal activity and expression studies in vitro.

Among the genes showing the most pronounced expression changes after exposure to 5 μM cocaine, we selected some showing functions that could potentially mediate cocaine effects and participate in neuronal circuit remodeling and neuroadaptations that lead to cocaine dependence. We succeeded in validating expression changes for seven of the eight selected genes, ENCI, NFAT5, ELF1, PPP1R9A, SEMA6D, IGF2BP3 and NRG1, whose expression had not previously been described to be altered after exposure to cocaine. ENCI (NRP/B) is primarily expressed in neurons and encodes an actin-binding protein that induces neurite outgrowth and has a role in nervous system development and differentiation.49,50 PPP1R9A is also expressed in neurons; it encodes Neurabin-1, a synaptic protein that controls neuronal actin cytoskeleton and reorganization and is involved in neurite formation.51,52 Semaphorin 6D, encoded by SEMA6D, is involved in axon guidance, and SNPs in this gene have previously been associated with substance dependence in a genome-wide association study.28,53,54 Other semaphorins have also been found upregulated by cocaine in animal and human studies.44,55 IGF2BP3 is involved in neuronal differentiation and Neuregulin1, encoded by NRG1, is a signaling protein that mediates cell-to-cell interactions, neuronal survival, synaptic maturation and maintenance, growth cone dynamics and trafficking of neurotransmitter receptors.56,57 Both ELF-1 and NFAT5 encode transcription factors that have been studied mainly in lymphoid cells and immune response. ELF-1 binds to the EBS elements of NFAT1, another NFAT family member.58

We subsequently considered these seven genes, which could mediate cocaine’s effects and neuroadaptations, as candidates for participating in the susceptibility to cocaine dependence.
Table 1. SNPs associated with cocaine dependence in the NFAT5 gene in a Spanish sample of 806 cocaine-dependent patients and 817 controls.

| Locus Marker | 11 | 12 | 22 | Sum | 11 | 12 | 22 | Sum |
|--------------|----|----|----|-----|----|----|----|-----|
| rs1437134    | G>A | 384 (47.3) | 386 (47.3) | 370 (46.1) | 1140 (140) | 264 (32.3) | 260 (32.3) | 252 (30.5) | 786 (97) |
| rs7359336    | A>G | 83 (10.3) | 81 (10.0) | 79 (9.6) | 243 (29) | 18 (2.2) | 15 (1.9) | 16 (1.9) | 53 (6.5) |
| rs11641233   | C>T | 816 (101) | 817 (101) | 817 (101) | 2450 (300) | 817 (101) | 817 (101) | 817 (101) | 2450 (300) |
| rs9952934    | A>G | 78 (9.6) | 78 (9.6) | 78 (9.6) | 234 (29) | 11 (1.3) | 11 (1.3) | 11 (1.3) | 33 (4) |
| rs12242510   | G>A | 836 (103) | 815 (101) | 836 (103) | 2487 (304) | 815 (101) | 815 (101) | 815 (101) | 2487 (304) |

Abbreviations: CI, confidence interval; miRNA, microRNA; OR, odds ratio; SNP, single-nucleotide polymorphism. *Log-additive model. **Adjusted by age. ***Survive Bonferroni correction.

Functional SNPs in these genes, selected as potential risk factors for this phenotype, were assessed in our Spanish sample of cocaine-dependent patients and controls. Our case–control association study with common genetic variants pointed to five SNPs in NFAT5 as risk factors for cocaine dependence, with rs1437134 surviving the Bonferroni correction for multiple testing and showing evidence of functional effects on gene expression. The risk allele for cocaine dependence, rs1437134, determined a decreased NFAT5 expression, an effect that was more pronounced in the presence of the microRNA hsa-miR-509 in the two cell lines tested. Previous studies support a link between the effects of cocaine and microRNAs. Cocaine chronic exposure resulted in increased Ago2 messenger RNA and protein in the striatum (a key brain region involved in addiction), and consequently an alteration of microRNA expression levels. Also, cocaine administration induced expression changes in a wide range of microRNAs in dopaminergic neurons in the striatum. A subset of these microRNAs upregulate genes known to influence the motivational properties of cocaine in mice, such as Bdnf, Fosb and CalcS1. Additional evidence suggesting that cocaine may exert its effects on gene expression through the regulation of the microRNA machinery was also found in our study, as an enrichment of predicted binding sites for miR-124a was observed among the list of genes found upregulated by cocaine. Interestingly, miR-124a has previously been reported to be down-regulated in SH-SY5Y cells after exposure to cocaine and in the mesolimbic dopaminergic system after chronic cocaine administration.

Our expression and case–control association studies suggest that NFAT5 may contribute to the vulnerability to cocaine dependence, which is in agreement with previous evidence suggesting that cocaine-induced activation of gene expression may be partially mediated by NFAT-dependent transcription. Transcription regulated by NFAT is shown to be induced by DA receptor stimulation. Cocaine triggers striatal NFAT4c nuclear translocation, possibly through a DA increase in the synaptic cleft produced by this drug. Interestingly, NFAT5 was present in the gene network identified, and NFAT canonical pathways were significantly over-represented in our gene expression study (Figure 1b; Supplementary Figures 2 and 5), which means that several genes regulated by NFAT or encoding related proteins are also differentially expressed after cocaine exposure. The NFAT family is involved in axonal growth and guidance by calcineurin/NFAT signaling pathway. NFAT5 (also known as TonEBP), however, differs from the other family members, as it does not have the calcineurin-binding domain. It has been involved in regulating response to osmotic stress and hypertonicity in several cell types, including T cells, kidney and neurons, and its activation also upregulates its own transcription. It is highly expressed in the brain at embryonic stages, but little is known about its function in the brain. Interestingly, a recent study suggests that NFAT5 could participate in DA synthesis and secretion in renal proximal tubule cells. Interestingly, a recent study suggests that NFAT5 could participate in DA synthesis and secretion in renal proximal tubule cells. If NFAT5 is involved in DA neurotransmission in the brain, genetic variants within this gene may predispose to cocaine dependence through changes in DA activity, this would be in agreement with the ‘reward deficiency syndrome’ hypothesis, which postulates that hypodopaminergic activity predisposes to cocaine addiction.

Considering all these data, NFAT5, a transcription factor, could be an important mediator of cocaine’s effects by activating NFAT-dependent transcription as well as dopaminergic activity. Cocaine might activate NFAT5 nuclear translocation, as it was shown for another member of the NFAT family, being responsible for cocaine-induced changes in gene expression, including its own upregulation. It is thus tempting to speculate that genetic variants impacting NFAT5 will cause an effect on the expression of relevant downstream genes and on DA activity, which could eventually contribute to cocaine dependence phenotypes.
This study should be viewed in terms of several strengths and limitations. Some strengths are as follow: (i) through a comprehensive hypothesis-free study, we have identified variants in a gene that seem to have a functional impact and that may participate in cocaine dependence; (ii) gene expression changes detected with microarrays were validated and are consistent with other studies; (iii) the clinical sample was evaluated by members of the research team in a single hospital following the same clinical assessment; (iv) all individuals, cases and controls, were Spanish, Caucasian and from the same small geographical area in Barcelona, Spain. Some limitations of the study, however, should be recognized: (i) cocaine effects on gene expression and neuronal activity were performed in a dopaminergic neuron-like model, from a tumor cell line, and thus they may differ from those taking place in the brain; (ii) the limited number of replicas in the microarray study may have prevented us from identifying existing differences in gene expression; (iii) in the association study, SNPs in the candidate genes were not selected under genetic coverage criteria, and thus, other variants not tested by us may be involved in cocaine dependence predisposition; (iv) cocaine dependence was not discarded in the control sample, which could lead to false-negative findings in our association study; (v) the SNPs found associated were not assessed in a replication sample; (vi) the functional effect of SNPs on microRNA regulation was studied in vitro with a reporter system and overexpressing the microRNAs, and may differ considerably from real conditions; (vii) we had a large sample for the neuroimaging genetics study, but we only tested few brain phenotypes, based on earlier findings on regions of interest to addiction rather than testing brain-wide effects.

To sum up, our data indicate that cocaine-induced changes in gene expression occur in differentiated SH-SY5Y cells a few hours after exposure to the drug, which are related to regulation of transcription and gene expression, cellular movement and neuronal adaptations. These changes occur at 5 μM cocaine, a concentration that increases neuronal activity and firing. Additional evidence suggests that a common functional variant in one of the genes showing increased expression after cocaine exposure, rs1437134 in NFAT5, may contribute to cocaine dependence. However, further genetic and functional studies of NFAT5 are needed to confirm its role in cocaine dependence.
CONFLICT OF INTEREST
BF received a speaker fee from Merz. The remaining authors declare no conflict of interest for this research.

ACKNOWLEDGMENTS
We are grateful to all the patients, their families and clinical collaborators who contributed with the patient recruitment (Carmen Baral, Nieves Martinez-Luna, Jesus Perez-Pazos, Alfonso Abad and Laia Rodriguez-Cintas). We thank Felix Junyent, Hector Diaz, Eulalia Marti, Monica Cozar, Javier Orlandi and Concepcion Arenas for helpful suggestions with cell culture, differentiation, western blot, neuronal activity and statistical analyses. This work made use of the BIG (Brain Imaging Genetics) database, first established in Nijmegen, the Netherlands, in 2007. This resource is now part of Cognomics (http://www.cognomics.nl), a joint initiative by researchers of the Donders Centre for Cognitive Neuroimaging, the Human Genetics and Cognitive Neuroscience Departments of the Radboud University Medical Center and the Max Planck Institute for Psycholinguistics in Nijmegen. We thank all persons who kindly participated in the BIG research. NF-C and JC-D were supported by contracts of the ‘Centro de Investigación Biomédica en Red de Enfermedades Raras’ (CIBERER), and JC-D was additionally supported by ‘Generalitat de Catalunya’ (2015 FI_00448). Major financial support for this research was received by BC from the Spanish ‘Ministerio de Economía y Competitividad’ (SAF2012-33848) and AGAUR, ‘Generalitat de Catalunya’ (2015SGR303). JS acknowledges financial support from the Spanish ‘Ministerio de Ciencia e Innovación’ (FIS2011-28820-C02-01 and FIS2013-41144-P) and from ‘Generalitat de Catalunya’ (2009SGR14 and 2014SGR878). MR is a recipient of a Miguel de Servet contract from the ‘Instituto de Salud Carlos III’, Spain (CP09/00119) and CS-M was supported by the European Community’s Seventh Framework Programme (FP7HEALTH2013-602805, Aggressortype). MR received financial support from ‘Instituto de Salud Carlos III’ (PII/11/0571, PII/12/0139, PII/12/0170), and by the European Regional Development Fund (ERDF) and AGAUR, ‘Generalitat de Catalunya’ (2014SGR1357). CR received financial support from ‘Instituto de Salud Carlos III’ (PII/11/0571) and Plan Nacional Sobre Drogas (CP09/00119) and CS-M was supported by the European Community’s Seventh Framework Programme (FP7HEALTH2013-602805, Aggressortype) and from the European Community’s Horizon 2020 Programme (grant agreement number 643051, MiND).

REFERENCES
1 Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997; 386: 827–830.
2 Pettit HO, Justice JB Jr. Dopamine in the nucleus accumbens during cocaine self-administration as studied by in vivo microdialysis. Pharmacol Biochem Behav 1989; 34: 889–904.
3 Ritz MC, Cone EJ, Kuhar MJ. Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: a structure-activity study. Life Sci 1990; 46: 635–645.
4 Lull ME, Freeman WM, Vrana KE, Mash DC. Correlating human and animal studies of cocaine abuse and gene expression. Ann N Y Acad Sci 2008; 1141: 58–75.
5 Yufner V, Nielsen D, Butelman E, Kreek MJ. Microarray studies of psychostimulant-induced changes in gene expression. Addict Biol 2005; 10: 101–118.
6 Nestler EJ. Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2001; 2: 119–128.
7 Nestler EJ. Genes and addiction. Nat Genet 2000; 26: 277–281.
8 Wagner FA, Anthony JC. From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology 2002; 26: 479–488.
9 Kendler KS, Karkowski LM, Neale MC, Prescott CA. Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. Arch Gen Psychiatry 2000; 57: 261–269.
10 Kendler KS, Prescott CA. Cocaine use, abuse and dependence in a population-based sample of female twins. Br J Psychiatry 1998; 173: 345–350.
11 Buhler KM, Gine E, Echevery-Alzate V, Calleja-Conde J, de Fonseca FR, Lopez-Moreno JA. Common single nucleotide variants underlying drug addiction: more than a decade of research. Addict Biol 2015; 20: 845–871.
12 Ballon N, Leroy S, Roy C, Bourdel MC, Olle JP, Charles-Nicolas A et al. Polymorphisms TaqA of the DRD2, Ball of the DRD3, exon III repeat of the DRD4, and 3’ UTR VNTR of the DAT: association with childhood ADHD in male African-Caribbean cocaine dependents? Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 1034–1041.
13 Hall FS, Draganova J, Jain S, Uhl GR. Implications of genome wide association studies for addiction: are we a priori assumptions all wrong? Pharmacol Ther 2013; 140: 267–279.
14 Fernandez-Castillo N, Cordem B, Roncero C, Sanchez-Mora C, Grau-Lopez L, Gonzalez B et al. Candidate pathway association study in cocaine dependence: the control of neurotransmitter release. World J Biol Psychiatry 2012; 13: 126–134.
15 Fernandez-Castillo N, Roncero C, Grau-Lopez L, Barral C, Prat G, Rodriguez-Cintas L et al. Association study of 37 genes related to serotonin and dopamine neurotransmission and neurotrophic factors in cocaine dependence. Genes Brain Behav 2013; 12: 39–46.
16 Gelernter J, Sherva R, Koesterer R, Almasy L, Zhao H, Kranzler HR et al. Genome-wide association study of cocaine dependence and related traits: FAM5B identified as a risk gene. Mol Psychiatry 2014; 19: 717–723.
17 Yu Y, Kranzler HR, Panhuysen C, Weiss RD, Poling J, Ferra L et al. Substance dependence low-density whole genome association study in two distinct American populations. Hum Genet 2008; 123: 495–506.
18 Ellenhorn M, Barcelous DG. Medical Toxicology. Elsevier: New York, NY, USA, 1988; 644–661.
19 Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor RR et al. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse 1989; 4: 371–377.
20 Poly D, Jatlow P, Van Dyke C, Jeri FR, Byck R. Plasma cocaine concentrations during repeated oral administration: development of a human laboratory model of chronic cocaine use. J Anal Toxicol 1998; 22: 435–444.
21 Crawford FC, Wood ML, Wilson SE, Mathura VS, Hollen TR, Geall F et al. Cocaine induced inflammatory response in human neuronal progenitor cells. J Neuromech 2006; 97: 662–674.
22 Paly D, Jatlow P, Van Dyke C, Jeri FR, Byck R. Plasma cocaine concentrations during cocaine paste smoking. Life Sci 1982; 30: 731–738.
23 Strawbridge RJ, Jatlow P, Van Dyke C, Byck R, Kranzler HR. Plasma cocaine concentrations during intranasal administration in man. Science 1976; 191: 859–861.
24 Irizarry RA, Wash NC, Lies J, Kranzler HR. Plasma cocaine concentrations in intranasal administration. J Psychopharmacol 2008; 22: 1–9.
25 Crawford FC, Wood ML, Wilson SE, Mathura VS, Hollen TR, Geall F et al. Cocaine induced inflammatory response in human neuronal progenitor cells. J Neuromech 2006; 97: 662–674.
26 Orlandi JC, Savijani SA, Yahn-Valencia E, Keil J, Kranzler HR et al. The emergence of coherent activity in neuronal cultures. Nat Phys 2013; 9: 582–590.
27 Roncero C, Daigre C, Barral C, Ros-Cucurull E, Grau-Lopez L, Rodriguez-Cintas L et al. Neurotrophin associated with cocaine-induced psychosis in cocaine-dependent patients: a cross-sectional observational study. PLoS One 2014; 9: e106111.
28 Drion T, Zhang PW, Johnson C, Walther D, Hess J, Nino M et al. Genome wide association for addiction: replicated results and comparisons of two analytic approaches. PLoS One 2010; 5: e8882.
29 Guadalupe T, Zwiers MP, Teumer A, Wittenfeld K, Vasquez AA, Hoogman M et al. Measurement and genetics of human subcortical and hippocampal asymmetries in large datasets. Hum Brain Mapp 2014; 35: 3277–3289.
30 Volkow ND, Fowler JS, Wang GJ. The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropsychopharmacology 2004; 27: 3–13.
31 Inzirri RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Sherf O et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Bioinformatics 2003; 4: 249–264.
32 Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44–57.
33 Zhang B, Kirov S, Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 2005; 33: W741–W748.
34 Gonzalez JR, Armengol L, Sole X, Guino E, Mercader JM, Estivill X et al. Functional genomics studies for addiction: are our a priori assumptions all wrong? Mol Psychiatry 2014; 19: 717–723.
35 Lopes FM, Schroder R, da Frota ML Jr, Zanotto-Filho A, Muller CB, Pires AS et al. Association study of 37 genes related to serotonin and dopamine neurotransmission and neurotrophic factors in cocaine dependence. Genes Brain Behav 2013; 12: 39–46.
Talmaigne DA. Mechanisms of neuregulin action. Novartis Found Symp 2008; 289: 74–84.

Thompson CB, Wang CY, Ho IC, Bohjanen PR, Petryniak B, June CH et al. cis-acting sequences required for inducible interleukin-2 enhancer function bind a novel Ets-related protein, Elf-1. Mol Cell Biol 1992; 12: 1043–1053.

Epper-Mains JE, Kiraly DD, Palakodeti D, Mains RE, Epper BA, Greavel BR. microRNA-Seq reveals cocaine-regulated expression of striatal microRNAs. RNA 2011; 17: 1529–1543.

Schaefer A, Im HI, Veno MT, Fowler CD, Min A, Intrator A et al. Argonaute 2 in dopamine 2 receptor-expressing neurons regulates cocaine addiction. J Exp Med 2010; 207: 1843–1851.

Rodrigues AC, Li X, Radecki L, Pan YZ, Winter JC, Huang M et al. MicroRNA expression is differentially altered by xenobiotic drugs in different human cell lines. Biopharm Drug Dispos 2011; 32: 355–367.

Chandrasekar V, Dreyer JL. microRNAs miR-124, let-7d and miR-181a regulate cocaine-induced plasticity. Mol Cell Neurosci 2009; 42: 350–362.

Groth RD, Weck JP, Bradley KC, Luoma JI, Aravamudan B, Klug JR et al. D1 dopamine receptor activation of NFAT-mediated striatal gene expression. Eur J Neurosci 2008; 27: 31–42.

Halterman JA, Kwon HM, Wamhoff BR. Toxicity-independent regulation of the osmosensitive transcription factor TonEBP (NFATS). Am J Physiol Cell Physiol 2012; 302: C1–C8.

Nguyen T, Di Giovanni S. NFAT signaling in neural development and axon growth. Int J Dev Neurosci 2006; 24: 141–145.

Aramburu J, Drews-Elger K, Estrada-Gelonch A, Minguillon J, Morancho B, Santiago V et al. Regulation of the hypertonic stress response and other cellular functions by the Rel-like transcription factor NFATS. Biochem Pharmacol 2006; 72: 1597–1604.

Maallem S, Berod A, Mutin M, Kwon HM, Tappaz ML. Large discrepancies in cellular distribution of the toxicity-induced expression of osmoprotective genes and their regulatory transcription factor TonEBP in rat brain. Neuroscience 2006; 142: 355–368.

Maallem S, Mutin M, Kwon HM, Tappaz ML. Differential cellular distribution of toxicity-induced expression of transcription factor TonEBP in the rat brain following prolonged systemic hypertonicity. Neuroscience 2006; 137: 51–71.

Loyer ML, Mutin M, Woo SK, Kwon HM, Tappaz ML. Translation factor toxicity-responsive enhancer-binding protein (TonEBP) which transactivates osmoprotective genes is expressed and upregulated following acute systemic hypertonicity in neurons in brain. Neuroscience 2004; 124: 89–104.

Maouyo D, Kim YJ, Lee SD, Wu Y, Woo SK, Kwon HM. Mouse TonEBP-NFAT5: expression in early development and alternative splicing. Am J Physiol Renal Physiol 2002; 282: F809–F809.

Hsin YH, Tang CH, Lai HT, Lee TH. The role of TonEBP in regulation of AAD expression and dopamine production in renal proximal tubule cells upon hypertonic challenge. Biochem Biophys Res Commun 2011; 414: 598–603.

Comings DE, Blum K. Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog Brain Res 2000; 126: 325–341.